Evidence map›Paper›PMID 30050129›Full record

ArticleNature communications2018

FABP4 as a key determinant of metastatic potential of ovarian cancer.

Kshipra M Gharpure, Sunila Pradeep, Marta Sans, Rajesha Rupaimoole, Cristina Ivan, Sherry Y Wu, Emine Bayraktar, Archana S Nagaraja, Lingegowda S Mangala, Xinna Zhang and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 1 synthesis or guideline pooled it, 210 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 5 institutions in 3 countries.

Kshipra M GharpureDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Sunila PradeepDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Marta SansDepartment of Chemistry, The University of Texas at Austin, Austin, TX, 78712, USA.ORCID http://orcid.org/0000-0002-7756-5101
Rajesha RupaimooleDepartment of Pathology and Institute of RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center, Harvard Medical School, Boston, MA, 02215, USA.
Cristina IvanCenter for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.ORCID http://orcid.org/0000-0002-4848-0168
Sherry Y WuDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Emine BayraktarDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Archana S NagarajaDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Lingegowda S MangalaDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Xinna ZhangCenter for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
Monika HaemmerleMartin-Luther-University Halle-Wittenberg, Institute of Pathology, 06112, Halle (Saale), Germany.
Wei HuDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Cristian Rodriguez-AguayoCenter for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.ORCID http://orcid.org/0000-0002-7880-7723
Michael McGuireDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Celia Sze Ling MakDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Xiuhui ChenDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Michelle A TranDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Alejandro Villar-PradosDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
Guillermo Armaiz PenaDepartment of Pharmacology, Ponce Health Sciences University, Ponce, 00716, Puerto Rico.
Ragini KondetimmanahalliThe University of Texas at Austin, Austin, TX, 78712, USA.
Ryan NiniGraduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-1201-0954
Pranavi KoppulaDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Prahlad RamDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jinsong LiuDepartment of Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Gabriel Lopez-BeresteinCenter for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA.
Keith BaggerlyDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Livia S EberlinDepartment of Chemistry, The University of Texas at Austin, Austin, TX, 78712, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. asood@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USThe University of Texas at Austin · USBeth Israel Deaconess Medical Center · USMartin Luther University Halle-Wittenberg · DEPonce Health Sciences University · PR

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9M
Harnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0M
Platelets promote growth of ovarian cancerR01CA177909 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AFSHAR-KHARGHAN, VAHID, SOOD, ANIL K · 2013 to 2023
$4.1M
Novel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2M
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modelingU01CA213759 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOPEZ-BERESTEIN, GABRIEL · 2017 to 2021
$2.5M
Mass Spectrometry Imaging for Clinical Diagnosis and Prognosis of Human CancersR00CA190783 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI SCHIAVINATO EBERLIN, LIVIA · 2016 to 2018
$677k
NCATS NIH HHS UH3 TR000943NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA217685NCI NIH HHS R00 CA190783NCI NIH HHS R01 CA177909NCI NIH HHS R35 CA209904NCI NIH HHS U01 CA213759
6 · The paper itself

Abstract

The standard treatment for high-grade serous ovarian cancer is primary debulking surgery followed by chemotherapy. The extent of metastasis and invasive potential of lesions can influence the outcome of these primary surgeries. Here, we explored the underlying mechanisms that could increase metastatic potential in ovarian cancer. We discovered that FABP4 (fatty acid binding protein) can substantially increase the metastatic potential of cancer cells. We also found that miR-409-3p regulates FABP4 in ovarian cancer cells and that hypoxia decreases miR-409-3p levels. Treatment with DOPC nanoliposomes containing either miR-409-3p mimic or FABP4 siRNA inhibited tumor progression in mouse models. With RPPA and metabolite arrays, we found that FABP4 regulates pathways associated with metastasis and affects metabolic pathways in ovarian cancer cells. Collectively, these findings demonstrate that FABP4 is functionally responsible for aggressive patterns of disease that likely contribute to poor prognosis in ovarian cancer.

Indexed as

AnimalsCell Line, TumorFatty Acid-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansMiceMice, NudeMicroRNAsNeoplasm InvasivenessOvarian NeoplasmsFABP4 protein, humanFatty Acid-Binding ProteinsMicroRNAsMIRN409 microRNA, human

Identifiers

PMID30050129
PMCPMC6062524
OpenAlexW2883694743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.